UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2013
INCYTE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware |
|
0-27488 |
|
94-3136539 |
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer |
Experimental Station |
|
|
Route 141 & Henry Clay Road |
|
|
Building E336 |
|
|
Wilmington, DE |
|
19880 |
(Address of principal executive offices) |
|
(Zip Code) |
(302) 498-6700
(Registrants telephone number,
including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
Attached hereto as Exhibit 99.1 and incorporated by reference herein is a press release dated November 6, 2013, announcing a proposed private offering of convertible senior notes by Incyte Corporation.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press release issued by Incyte Corporation dated November 6, 2013.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 6, 2013 |
| |
|
| |
|
INCYTE CORPORATION | |
|
| |
|
| |
|
By: |
/s/ David C. Hastings |
|
|
David C. Hastings |
|
|
Executive Vice President and |
|
|
Chief Financial Officer |
Exhibit 99.1
FOR IMMEDIATE RELEASE
Pamela M. Murphy
Vice President, Investor Relations & Corporate Communications
(302) 498-6944
Incyte Announces Proposed Offering of $700 Million of Convertible Senior Notes
Notes to be offered in Two $350 Million Series, Due in 2018 and 2020
Up to $500 million of offering proceeds to be used for repurchase or retirement of existing
convertible notes
WILMINGTON, DE November 6, 2013 Incyte Corporation (Nasdaq: INCY) today announced its intention to offer, subject to market and other conditions, $350 million aggregate principal amount of convertible senior notes due 2018 and $350 million aggregate principal amount of convertible senior notes due 2020 in a private placement to qualified institutional buyers pursuant to an exemption from the registration requirements of the Securities Act of 1933. Incyte expects to grant the initial purchasers of the notes an option to purchase up to an additional $25 million aggregate principal amount of each series of the notes.
Entities affiliated with Julian C. Baker, a director of the Company, have indicated an interest in purchasing up to $500 million aggregate principal amount of notes in this offering.
The Company intends to use up to $500 million of the net proceeds from this offering to repurchase or otherwise retire a portion of the Companys 4.75% convertible senior notes due 2015, through open market transactions, negotiated transactions or otherwise. The Company has indicated an interest in repurchasing, and entities affiliated with Mr. Baker have indicated an interest in selling to the Company, convertible notes held by those entities with a value of up to $500 million, in a privately negotiated transaction. The Company intends to use the remainder of the net proceeds from this offering to continue investing in research and development, and for other general corporate purposes.
The notes will bear cash interest, payable semi-annually, and will not be redeemable prior to maturity. The notes will be convertible only during certain periods and subject to certain circumstances, into cash, shares of Incytes common stock, or a combination of cash and shares of Incytes common stock, at Incytes election. Final terms of each series of notes, including interest rates, conversion rates and other terms, will be determined at the time of pricing.
Goldman, Sachs & Co., J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers for this offering.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. The notes and the common stock issuable upon conversion of the notes have not been registered under the Securities Act of 1933 or applicable state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act of 1933 and applicable state securities laws.
Forward-Looking Statements
Because indications of interest are not binding agreements or commitments to purchase, the Baker entities may purchase a lesser amount or no notes in the offering. Except for the historical information contained herein, the matters set forth in this press release, including statements with respect to the intention to offer the notes, the intended use of net proceeds from the offering and the expected terms of the offering, are all forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including difficulties or delays in pricing or closing the proposed offering, fluctuations in the price of the Incytes common stock, satisfaction of the conditions to closing of the offering, uncertainties associated with the repurchase and retirement of outstanding debt, unanticipated costs in research and development efforts or other unanticipated cash requirements, and other risks detailed from time to time in Incytes filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013. Incyte disclaims any intent or obligation to update these forward-looking statements.